Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019028040) MODIFIED DDAH POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY, IMPROVED PHARMACOLOGY AND THEIR USES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/028040 International Application No.: PCT/US2018/044627
Publication Date: 07.02.2019 International Filing Date: 31.07.2018
IPC:
A61K 38/50 (2006.01) ,C12N 9/78 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43
Enzymes; Proenzymes; Derivatives thereof
46
Hydrolases (3)
50
acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9
Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14
Hydrolases (3.)
78
acting on carbon to nitrogen bonds other than peptide bonds (3.5)
Applicants:
VASCULONICS LLC [US/US]; 13662 Frenchmans Ck Carmel, Indiana 46032, US
Inventors:
SINGH, Jaipal; US
Agent:
ZUCCHERO, Anthony J.; US
HALL, Miles E.; US
Priority Data:
62/539,26131.07.2017US
Title (EN) MODIFIED DDAH POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY, IMPROVED PHARMACOLOGY AND THEIR USES
(FR) POLYPEPTIDES DDAH MODIFIÉS COMPRENANT UN FRAGMENT D'AMÉLIORATION PHARMACOCINÉTIQUE, À PHARMACOLOGIE AMÉLIORÉE ET LEURS UTILISATIONS
Abstract:
(EN) Modified DDAH polypeptides and their uses thereof are provided. Exemplary embodiments provide DDAH polypeptides which include one or more amino acid substitutions, additions, or deletions with natural or non-naturally encoded amino acids, and/or linkage to other biologically active molecules including other DDAH polypeptides, as well as PKEM. Additionally, use of said DDAH polypeptides for treatment of disease, such as heart failure or renal disease, is also provided.
(FR) La présente invention concerne des polypeptides DDAH modifiés et leurs utilisations. Des modes de réalisation donnés à titre d'exemple concernent des polypeptides DDAH qui comprennent une ou plusieurs substitutions, additions ou délétions d'acides aminés par des acides aminés naturels ou codés de manière non naturelle, et/ou une liaison à d'autres molécules biologiquement actives dont d'autres polypeptides DDAH, ainsi que PKEM. De plus, l'utilisation desdits polypeptides DDAH pour le traitement d'une maladie, telle que l'insuffisance cardiaque ou une maladie rénale est en outre décrite.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)